Switzerland
· Delayed Price · Currency is CHF Addex Therapeutics Statistics
Total Valuation
Addex Therapeutics has a market cap or net worth of CHF 6.49 million. The enterprise value is 3.18 million.
| Market Cap | 6.49M |
| Enterprise Value | 3.18M |
Important Dates
The next estimated earnings date is Monday, March 24, 2025.
| Earnings Date | Mar 24, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Addex Therapeutics has 98.32 million shares outstanding. The number of shares has increased by 42.00% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 98.32M |
| Shares Change (YoY) | +42.00% |
| Shares Change (QoQ) | -41.48% |
| Owned by Insiders (%) | 18.99% |
| Owned by Institutions (%) | 2.90% |
| Float | 34.26M |
Valuation Ratios
The trailing PE ratio is 1.20.
| PE Ratio | 1.20 |
| Forward PE | n/a |
| PS Ratio | 10.60 |
| PB Ratio | 0.59 |
| P/TBV Ratio | 0.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.59 |
| EV / Sales | 5.38 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.53 |
Financial Position
The company has a current ratio of 4.59, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.59 |
| Quick Ratio | 4.36 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | -506.88 |
Financial Efficiency
Return on equity (ROE) is -168.91% and return on invested capital (ROIC) is -90.07%.
| Return on Equity (ROE) | -168.91% |
| Return on Assets (ROA) | -75.64% |
| Return on Capital (ROIC) | -90.07% |
| Revenue Per Employee | 25,755 |
| Profits Per Employee | 234,986 |
| Employee Count | 23 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +43.48% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +43.48% |
| 50-Day Moving Average | 0.07 |
| 200-Day Moving Average | 0.08 |
| Relative Strength Index (RSI) | 56.34 |
| Average Volume (20 Days) | 283,016 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Addex Therapeutics had revenue of CHF 592,361 and earned 5.40 million in profits. Earnings per share was 0.05.
| Revenue | 592,361 |
| Gross Profit | -6.09M |
| Operating Income | -11.08M |
| Pretax Income | -12.67M |
| Net Income | 5.40M |
| EBITDA | -10.89M |
| EBIT | -11.08M |
| Earnings Per Share (EPS) | 0.05 |
Balance Sheet
The company has 3.35 million in cash and 43,767 in debt, giving a net cash position of 3.31 million or 0.03 per share.
| Cash & Cash Equivalents | 3.35M |
| Total Debt | 43,767 |
| Net Cash | 3.31M |
| Net Cash Per Share | 0.03 |
| Equity (Book Value) | 11.06M |
| Book Value Per Share | 0.11 |
| Working Capital | 3.18M |
Cash Flow
In the last 12 months, operating cash flow was -5.97 million and capital expenditures -2,478, giving a free cash flow of -5.98 million.
| Operating Cash Flow | -5.97M |
| Capital Expenditures | -2,478 |
| Free Cash Flow | -5.98M |
| FCF Per Share | -0.06 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,870.11% |
| Pretax Margin | -2,139.51% |
| Profit Margin | 912.40% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Addex Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -42.00% |
| Shareholder Yield | -42.00% |
| Earnings Yield | 79.75% |
| FCF Yield | -92.08% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Addex Therapeutics has an Altman Z-Score of -38.63. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -38.63 |
| Piotroski F-Score | n/a |